Improvement of adaptive immunity by antigen-carrying biodegradable nanoparticles

Biochemical and Biophysical Research Communications

Volumn 379, Issue 2, 2009, Pages 600-604

  Uto, Tomofumi ^a,c   Wang, Xin ^a,c   Akagi, Takami ^b,c   Zenkyu, Rika ^a   Akashi, Mitsuru ^b,c   Baba, Masanori ^a,c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Adaptive immunity; Adjuvant; Nanoparticle; Vaccine

Indexed keywords

ANTIGEN; CD8 ANTIGEN; FREUND ADJUVANT; NANOPARTICLE; OVALBUMIN; POLYGLUTAMIC ACID;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BIODEGRADABILITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNITY, INNATE; IMMUNIZATION; MICE; MICE, INBRED C57BL; NANOPARTICLES; OVALBUMIN; POLYGLUTAMIC ACID;

MUS;

EID: 58149527437     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.122     Document Type: Article

References (19)

1. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., Bosio C., and Dow S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176 (2006) 7335-7345
2. Petrovsky N., and Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82 (2004) 488-496
3. Pashine A., Valiante N.M., and Ulmer J.B. Targeting the innate response with improved vaccine adjuvants. Nat. Med. 11 (2005) S63-S68
4. Moore A.C., and Hill A.V. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199 (2004) 126-143
5. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4 (1998) 397-402
6. Letvin N.L., Barouch D.H., and Montefiori D.C. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20 (2002) 73-99
7. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'neil C.P., Lee L.K., Swartz M.A., and Hubbell J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25 (2007) 1159-1164
8. Hu Y., Litwin T., Nagaraja A.R., Kwong B., Katz J., Watson N., and Irvine D.J. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett. 7 (2007) 3056-3064
9. Wang X., Uto T., Sato K., Ide K., Akagi T., Okamoto M., Kaneko T., Akashi M., and Baba M. Potent activation of antigen-specific T cells by antigen-loaded nanospheres. Immunol. Lett. 98 (2005) 123-130
10. Akagi T., Higashi M., Kaneko T., Kida T., and Akashi M. In vitro enzymatic degradation of nanoparticles prepared from hydrophobically-modified poly(γ-glutamic acid). Macromol. Biosci. 14 (2005) 598-602
11. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., and Baba M. Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J. Immunol. 178 (2007) 2979-2986
12. + T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. J. Virol. 81 (2007) 10009-10016
13. Singh M., Chakrapani A., and O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines 6 (2007) 797-808
14. Zhu M., Oishi K., Lee S.C., and Patterson P.H. Studies using leukemia inhibitory factor (LIF) knockout mice and a LIF Adenoviral Vector Demonstrate a key anti-inflammatory role for this cytokine cutaneous inflammation. J. Immunol. 166 (2001) 2049-2054
15. Yoshikawa T., Okada N., Oda A., Matsuo K., Mukai Y., Yoshioka Y., Akagi T., Akashi M., and Nakagawa S. Nanoparticles built by self-assembly of amphiphilic g-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine 26 (2008) 1303-1313
16. Wang X., Uto T., Akagi T., Akashi M., and Baba M. Poly(γ-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine. J. Med. Virol. 80 (2008) 11-19
17. + lymphocytes. Science 283 (1999) 857-860
18. + T lymphocytes. J. Immunol. 178 (2007) 3177-3185
19. Thomas M.J., Noble A., Sawicka E., Askenase P.W., and Kemeny D.M. CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation. J. Immunol. 168 (2002) 216-223